Trials / Completed
CompletedNCT05686096
A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435
A Phase 1, Open-label, Single Dose Study to Assess the Absorption, Metabolism, and Excretion of [14C]BMS-986435 in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the absorption, metabolism, excretion; and to evaluate the safety and tolerability of BMS-986435 in healthy male participants Participants will be admitted to the study site for 3 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MYK-224 | Specified dose on specified days |
Timeline
- Start date
- 2023-01-16
- Primary completion
- 2023-04-08
- Completion
- 2023-04-08
- First posted
- 2023-01-17
- Last updated
- 2023-05-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05686096. Inclusion in this directory is not an endorsement.